ABG-WTT Global Life Science Capital Partners GP Ltd

In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), ABG-WTT Global Life Science Capital Partners GP Ltd reported 3 stock positions worth $20.1 million. Its top holding was CG Oncology (CGON) at 92.9% of the portfolio, followed by Rapid Micro Biosystems Class A (RPID, 4.6%) and Pulmonx (LUNG, 2.5%). Compared with Q2 2024, it reduced 1. The biggest sale was CG Oncology (CGON, shares −46%).

Most Recent 13F
Q2 2026
Location
CENTRAL, HONG KONG, K3
CIK
0001832108
Portfolio Value
$20.1M (Q3 2024)
SEC Filing
0000950123-24-011466 ↗ filed Nov 14, 2024

Holdings Value

0$10.0M$20.0M$30.0M$40.0M$50.0M Q1 2024: $41.5M Q1 2024 Q2 2024: $30.0M Q2 2024 Q3 2024: $20.1M $20.1M Q3 2024 Q4 2024: $43.7M Q4 2024 Q1 2025: $38.3M Q1 2025 Q2 2025: $26.8M Q2 2025 Q3 2025: $18.7M Q3 2025 Q4 2025: $15.0M Q4 2025 Q1 2026: $12.3M Q1 2026 Q2 2026: $8.6M Q2 2026

Holdings 3 stocks · $20.1M
CGON CG Oncology Inc. 92.93% 495,526 $18.7M Reduce -45.9%
RPID Rapid Micro Biosystems Inc. Class A 4.59% 1,038,296 $924K No change
LUNG Pulmonx Corp. 2.48% 60,204 $499K No change

Portfolio Sells Q2 2024 → Q3 2024
CGON CG Oncology Inc. Reduce -45.9% 92.93% −3.51

Portfolio Buys Q2 2024 → Q3 2024
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 2$8.6MCBLL, RPID
Q1 2026 2$12.3MCBLL, RPID
Q4 2025 2$15.0MCBLL, RPID
Q3 2025 2$18.7MCBLL, RPID
Q2 2025 2$26.8MCBLL, RPID
Q1 2025 4$38.3MCBLL, CGON, RPID, LUNG
Q4 2024 4$43.7MCBLL, CGON, RPID, LUNG
Q3 2024 3$20.1MCGON, RPID, LUNG
Q2 2024 3$30.0MCGON, RPID, LUNG
Q1 2024 3$41.5MCGON, RPID, LUNG